Trials / Completed
CompletedNCT04008082
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
Specific Use Results Survey of LENVIMA 4 mg Capsules -Observational Study of Overall Survival in Patients With Unresectable Hepatocellular Carcinoma (Study LEN03T)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 412 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Lenvatinib capsule. |
Timeline
- Start date
- 2019-05-14
- Primary completion
- 2022-01-28
- Completion
- 2022-01-28
- First posted
- 2019-07-05
- Last updated
- 2022-03-08
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04008082. Inclusion in this directory is not an endorsement.